Amring Pharmaceuticals Inc. (Amring), a niche generic and brand pharmaceutical company, announced today that it has received FDA approval for generic Lamotrigine ODT, USP (25mg, 50mg, 100mg and 200mg) available in bottles of 30 tablets (AB rated generic equivalent of Lamictal®), and has begun commercialization activities.
Lamotrigine ODT, USP is indicated for:
-
Epilepsy adjunctive therapy in patients aged 2 years and older,
-
Epilepsy monotherapy in patients aged 16 years and older, and
-
Maintenance of bipolar I disorder in patients treated for acute mood episodes with standard therapy.
"We are pleased to add Lamotrigine Orally Disintegrating Tablets, USP to our generics portfolio. These products bring long term value to patients and customers in our target markets.” stated Daniel Carbery, President and CEO of Amring. “We look forward to realizing the benefits of these, and other product launches and future business development activities in 2022.”